Noninvasive Assessment of Tumor Hypoxia with 99mTc Labeled Metronidazole
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Purpose. The assessment of tumor hypoxia by imaging modality prior to radiation therapy would provide a rational means of selecting patients for treatment with radiosensitizers or bioreductive drugs. This study aimed to develop a 99mTc-labeled metronidazole (MN) using ethylene-dicysteine (EC) as a chelator and evaluate its potential use to image tumor hypoxia.
Methods. EC was conjugated to amino analogue of MN using Sulfo-N-hydroxysuccinimide and l-ethyl-3-(3-dimethylaminopropyl) carbodiimide-HCl as coupling agents, the yield was 55%. Tissue distribution of 99mTc-EC-MN was determined in breast tumor-bearing rats at 0.5, 2, and 4 hrs. Planar imaging and whole-body autoradiograms were performed. The data was compared to that using 99mTc-EC (control), [l8F]fluoromisonidazole (FMISO) and [131I] iodomisonidazole (IMISO).
Results. In vivo biodistribution of 99mTc-EC-MN in breast tumor-bearing rats showed increased tumor-to-blood and tumor-to-muscle ratios as a function of time. Conversely, tumor-to-blood values showed time-dependent decrease with 99mTc-EC in the same time period. Planar images and autoradiograms confirmed that the tumors could be visualized clearly with 99mTc-EC-MN from 0.5 to 4 hrs. There was no significant difference of tumor-to-blood count ratios between 99mTc-EC-MN and [131I]IMISO at 2 and 4 hrs postinjection. From 0.5 to 4 hrs, both 99mTc-EC-MN and [131I]IMISO have higher tumor-to-muscle ratios compared to FMISO.
Conclusions. It is feasible to use 99mTc-EC-MN to image tumor hypoxia.
- E. J. Hall. The oxygen effect and reoxygenation. In E. J. Hall (ed.) Radiobiology for the radiobiologist, 3rd edition. J. B. Lippincott Co., Philadelphia, PA, 1988, pp. 137-160.
- R. S. Bush, R. D. T. Jenkins, W. E. C. Allt, F. A. Beale, H. Bena, A. J. Dembo, and J. F. Pringle. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer 37(Suppl. III):302-306 (1978).
- L. H. Gray, A. D. Conger, M. Elbert, S. Morsney, and O.C.A. Scold. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 26:638-648 (1953).
- S. Dische. A review of hypoxic-cell radiosensitization. Int. J. Radiat. Oncol. Biol. Phys. 20:147-152 (1991).
- R. A. Gatenby, H. B. Kessler, J. S. Rosenblum, L. R. Coia, P. J. Moldofsky, W. H. Hartz, and G. J. Broder. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 14:831-838 (1988).
- M. Nordsmark, M. Overgaard, and J. Overgaard. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41:31-39 (1996).
- W-J Koh, J. S. Rasey, M. L. Evans, J. R. Grierson, T. K. Lewellen, M. M. Graham, K. A. Krohn, and T. W. Griffin. Imaging of hypoxia in human tumors with 18F fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys. 22:199-212 (1992).
- P. E. T. Valk, C. A. Mathis, M. D. Prados, J. C. Gilbert, and T. F. Budinger. Hypoxia in human gliomas: Demonstration by PET with [18F]fluoromisonidazole. J. Nucl. Med. 33:2133-2137 (1992).
- G. V. Martin, J. H. Caldwell, J. S. Rasey, Z. Grunbaum, M. Cerqueia, and K. A. Krohn. Enhanced binding of the hypoxic cell marker [18F]fluoromisonidazole in ischemic myocardium. J. Nucl. Med. 30:194-201 (1989).
- J. S. Rasey, W. J. Koh, J. R. Grieson, Z. Grunbaum, and K. A. Krohn. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J. Radiat. Oncol. Biol. Phys. 17:985-991 (1989).
- J. S. Rasey, N. J. Nelson, L. Chin, M. L. Evans, and Z. Grunbaum. Characterization of the binding of labeled fluoromisonidazole in cells in vitro. Radiat. Res. 122:301-308 (1990).
- D. J. Yang, S. Wallace, A. Cherif, C. Li, M. B. Gretzer, E. E. Kim, and D. A. Podoloff. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 194:795-800 (1995).
- A. Cherif, S. Wallace, D. J. Yang, R. Newman, V. Wilson, A. Nornoo, T. Inoue, C. Kim, L-R Kuang, E. E. Kim, and D. A. Podoloff. Development of new markers for hypoxic cells: [131I]io-domisonidazole and [131I]iodoerythronitroimidazole. J. Drug Targeting 4:31-39 (1996).
- B. A. Teicher and E. A. Sotomayor. Chemical radiation sensitizers and protectors. In W. O. Foye (ed.), Cancer Chemotherapeutic Agents, American Chemical Society, Washington, D. C., 1995, pp. 501-527.
- G. Johnson, K. N. Nguyen, Z. Lui, P. Gao, B. Edwards, C. M. Archer, A. C. King, T. L. North, R. D. Okada, and W. K. Warren. HL91 Technetium-99m: Kinetics of a new hypoxia avid imaging agent in normal and ischemic myocardium as assessed by gamma camera images. J. Am. Coll. Cardiol. 407A (1996).
- K. Fukuchi, H. Kusuoka, K. Yutani, S. Hasegawa, and T. Nishimura. Assessment of reperfused myocardium using new hypoxia avid imaging agent Tc-99m HL91. J. Nucl. Med. 37:94 (Abstract) (1996).
- T. Melo, J. Duncan, J. R. Ballinger, and A. M. Rauth. BMS 194796, a second generation Tc-99m labelled 2-nitroimidazole for imaging hypoxia in tumors. J. Nucl. Med. 39:219 (Abstract) (1998).
- X. Zhang, T. Melo, J. R. Ballinger, and A. M. Rauth. Evaluation of Tc-99m butyleneamino oxime (BnAO), a non-nitroaromatic agent for imaging hypoxia in tumors. J. Nucl. Med. 39:216 (Abstract) (1998).
- A. Davison, A. G. Jones, C. Orvig, and M. Sohn. A new class of oxotechnetium(+5) chelate complexes containing a TcON2S2 Core. Inorg. Chem. 20:1629-1632 (1981).
- A. M. Verbruggen, D. L. Nosco, C. G. Van Nerom, G. M. Bormans, P. J. Adriaens, and M. J. De Roo. Tc-99m-L,L-ethylenedicysteine: A renal imaging agent. I. Labelling and evaluation in animals. J. Nucl. Med. 33:551-557 (1992).
- C. G. Van Nerom, G. M. Bormans, M. J. De Roo, and A. M. Verbruggen. First experience in healthy volunteers with Tc-99m-L,L-ethylenedicysteine, a new renal imaging agent. Eur. J. Nucl. Med. 20:738-746 (1993).
- M. J. Surma, J. Wiewiora, and J. Liniecki. Usefulness of Tc-99m-N,N′-ethylene-1-dicysteine complex for dynamic kidney investigations. Nucl. Med. Comm. 15:628-635 (1994).
- S. Ratner and H. T. Clarke. The action of formaldehyde upon cysteine. J. Am. Chem. Soc. 59:200-206 (1937).
- P. Blondeau, C. Berse, and D. Gravel. Dimerization of an intermediate during the sodium in liquid ammonia reduction of L-thiazolidine-4-carboxylic acid. Can. J. Chem. 45:49-52 (1967).
- M. P. Hay, W. R. Wilson, J. W. Moselen, B. D. Palmer, and W. A. Denny. Hypoxia-selective antitumor agents. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitizers. J. Med. Chem. 37:381-391 (1994).
- A. Cherif, D. J. Yang, W. Tansey, E. E. Kim, and S. Wallace. Synthesis of [18F]fluoromisonidazole. Pharm. Res. 11:466-469 (1994).
- G. V. Martin, J. H. Cardwell, M. M. Graham, J. R. Grierson, K. Kroll, M. J. Xowna, T. K. Lewellen, J. S. Rasey, J. J. Casciari, and K. A. Krohn. Noninvasive detection of hypoxic myocardium using [18F]fluoromisonidazole and PET. J. Nucl. Med. 33:2202-2208 (1992).
- S. H. Yeh, R. S. Liu, H. H. Hu, C. P. Chang, L. S. Chu, K. L. Chou, and L. C. Wu. Ischemic penumbra in acute stroke: demonstration by PET with fluorine-18 fluoromisonidazole. J. Nucl. Med. 35:(5)205 (Abstract) (1994).
- S. H. Yeh, R. S. Liu, L. C. Wu, D. J. Yang, S. H. Yen, C. W. Chang, T. W. Yu, K. L. Chou, and K. Y. Chen. Fluorine-18 fluoromisonidazole tumor to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur. J. Nucl. Med. 23:1378-1383 (1996).
- R. S. Liu, S. H. Yeh, C. P. Chang, L. S. Chu, M. T. Lui, K. L. Chou, and L. C. Wu. Detection of odontogenic infections by [18F]fluoromisonidazole. J. Nucl. Med. 35:113 (Abstract) (1994).
- Noninvasive Assessment of Tumor Hypoxia with 99mTc Labeled Metronidazole
Volume 16, Issue 5 , pp 743-750
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- tumor hypoxia
- Industry Sectors